GlassScriptPhysician profile
Marvin H Lucas
NPI 1508820234
$4,549.33
in general payments reported to CMS, 2019-2025
35 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2020: $219 · 2021: $275 · 2022: $993 · 2023: $996 · 2024: $54.39 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $609.61 | 2019-2025 | |
| Novo Nordisk INC | $473.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $462.33 | 2019-2025 | |
| Amgen INC. | $429.44 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $333.38 | 2019-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $252.63 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Novartis Pharmaceuticals Corporation | $212.32 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.26 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $173.56 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $153.76 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $135.57 | 2022 | |
| Exact Sciences Corporation | $126.66 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.00 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $92.65 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $90.95 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $80.11 | 2023-2025 | |
| Amarin Pharma, INC. | $77.19 | 2019-2022 | |
| Dexcom, INC. | $76.53 | 2022-2025 | Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $62.50 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $47.06 | 2019-2025 | Zoryve |
| Hikma Pharmaceuticals USA | $40.86 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $40.20 | 2022-2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $31.83 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $29.19 | 2021 | |
| Sanofi Pasteur INC. | $23.79 | 2023 | |
| Merck Sharp & Dohme LLC | $23.34 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $22.08 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.00 | 2022 | |
| Medtronic USA, INC. | $18.93 | 2019 | |
| Abbott Laboratories | $17.07 | 2019 | |
| Corcept Therapeutics | $16.59 | 2025 | Korlym |
| Allergan, INC. | $15.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.81 | 2023 | Eliquis |
| Pulmonx Corporation | $14.41 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Shire North American Group INC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Lucas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.